SEC Comment Letter 0000000000-24-000488 to Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc.
Date: Jan. 16, 2024 · CIK: 0001400118 · Accession: 0000000000-24-000488
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo January 16, 2024 David Happel Chief Executive Officer Sagimet Biosciences Inc. 155 Bovet Road, Suite 303 San Mateo, CA 94402 Re:Sagimet Biosciences Inc. Draft Registration Statement on Form S-1 Submitted January 10, 2024 CIK No. 0001400118 Dear David Happel: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Porter, Esq.
Show Raw Text
United States securities and exchange commission logo
January 16, 2024
David Happel
Chief Executive Officer
Sagimet Biosciences Inc.
155 Bovet Road, Suite 303
San Mateo, CA 94402
Re:Sagimet Biosciences Inc.
Draft Registration Statement on Form S-1
Submitted January 10, 2024
CIK No. 0001400118
Dear David Happel:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jennifer Porter, Esq.